Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL682832 | 0.91 | MAPT (0.49) | MAPK1HTR2AMAPTADORA2BGLA | |
| SCHEMBL683707 | 0.89 | ADORA2B (0.45) | MAPK1HTR2ANPSR1MAPTADORA2B | |
| SCHEMBL683652 | 0.85 | MAPK1 (0.55) | MAPK1HTR2ANPSR1MAPTGLA | |
| SCHEMBL683664 | 0.84 | MAPK1 (0.56) | MAPK1NPSR1MAPTADORA2BGLA | |
| SCHEMBL682838 | 0.78 | HTR2A (0.57) | MAPK1HTR2ANPSR1ADORA2BGLA | |
| SCHEMBL684045 | 0.75 | MAPT (0.50) | MAPK1MAPTADORA2BGLAHTT | |
| SCHEMBL684023 | 0.75 | HTR2A (0.58) | MAPK1HTR2AADORA2BGLABLM | |
| SCHEMBL684026 | 0.75 | MAPK1 (0.49) | MAPK1HTR2ANPSR1MAPTADORA2B | |
| SCHEMBL682822 | 0.74 | RXFP1 (0.57) | MAPK1MAPTADORA2BGLAHTT | |
| SCHEMBL684068 | 0.74 | ADORA2B (0.50) | MAPK1HTR2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | MAPK1 470/4885HTR2A 1201/4885NPSR1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.